|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500105419 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-03 09:17:13 |
|
注册时间: Date of Registration: |
2025-07-03 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
医院孕妇队列研究易感基因和社会文化生态因素交互作用在妊娠期糖尿病中的致病作用 |
|
Public title: |
The pathogenic role of the interaction between susceptible genes and socio-cultural ecological factors in gestational diabetes mellitus: A hospital-based pregnant women cohort study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
医院孕妇队列研究易感基因和社会文化生态因素交互作用在妊娠期糖尿病中的致病作用 |
|
Scientific title: |
The pathogenic role of the interaction between susceptible genes and socio-cultural ecological factors in gestational diabetes mellitus: A hospital-based pregnant women cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙敏娴 |
研究负责人: |
张红梅 |
|
Applicant: |
Minxian Sun |
Study leader: |
Hongmei Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 158 7135 5415 |
研究负责人电话:
Study leader's |
+86 138 7126 9128 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
376253050@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
525040199@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市江汉区姑嫂树路16号 |
研究负责人通讯地址: |
湖北省武汉市江汉区姑嫂树路16号 |
|
Applicant address: |
No. 16 Gushao Tree Road, Jianghan District, Wuhan, Hubei Province |
Study leader's address: |
No. 16 Gushao Tree Road, Jianghan District, Wuhan, Hubei Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属武汉中心医院 |
||
|
Applicant's institution: |
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属武汉中心医院 |
||
|
Affiliation of the Leader: |
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
WHZXKYL2025-064 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉市中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Central Hospital of Wuhan |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-20 00:00:00 | ||
|
伦理委员会联系人: |
石小燕 |
||
|
Contact Name of the ethic committee: |
Shi Xiaoyan |
||
|
伦理委员会联系地址: |
湖北省武汉市江岸区胜利街26号 |
||
|
Contact Address of the ethic committee: |
No. 26 Shengli Street, Jiang'an District, Wuhan, Hubei Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 139 7168 2119 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属武汉中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市江汉区姑嫂树路16号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 16 Gushao Tree Road, Jianghan District,Wuhan, Hubei Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
武汉市科学技术局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Wuhan Science and Technology Bureau |
||||||||||||||||||||||
|
研究疾病: |
妊娠期糖尿病 |
||||||||||||||||||||||
|
Target disease: |
Gestational Diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本研究的目的是揭示葡萄糖激酶(glucokinase,GCK)基因、肝核因子1A(hepatic nuclear factors-1A,HNF1A),肝核因子4A(hepatic uclear factors-4A,HNF4A),褪黑素受体1B(melatonin receptor 1B, MTNR1B)等易感基因及其交互作用对GDM的影响,同时研究社会文化生态因素对GDM的影响,探讨社会文化生态因素与遗传易感基因多态性的交互作用机制,以及基因在社会文化生态因素的影响下有可能产生的累积效应作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
The aim of this study is to elucidate the impact of susceptible genes, including the glucokinase (GCK) gene, hepatic nuclear factor-1A (HNF1A), hepatic nuclear factor-4A (HNF4A), and melatonin receptor 1B (MTNR1B), as well as their interactions, on gestational diabetes mellitus (GDM). Additionally, this study investigates the influence of socio-cultural ecological factors on GDM, explores the interaction mechanisms between socio-cultural ecological factors and genetic susceptibility gene polymorphisms, and examines the potential cumulative effects of genes under the influence of socio-cultural ecological factors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄≥18岁;汉族;单胎妊娠;符合2010年IADPSG诊断标准:孕24-28周行75g口服葡萄糖耐量试验(OGTT),5.1mmol/L≤空腹血糖< 7.0mmol/L,OGTT 1h 血糖≥10.0 mmol/L,8.5 mmol/L≤OGTT 2h血糖<11.1 mmol/L,上述任一点血糖值达标即诊断GDM;在告知相关调查内容后愿意进入队列并接受相关问卷的调查和同意血液样本的收集,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Aged >=18 years; Han ethnicity; Singleton pregnancy; Meets the diagnostic criteria of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) in 2010: A 75g oral glucose tolerance test (OGTT) is performed at 24-28 weeks of gestation, with fasting blood glucose levels between 5.1 mmol/L and <7.0 mmol/L, 1-hour OGTT blood glucose ≥10.0 mmol/L, and 2-hour OGTT blood glucose between 8.5 mmol/L and <11.1 mmol/L. A diagnosis of gestational diabetes mellitus (GDM) is made if any one of the above blood glucose values is met; Willing to participate in the cohort study and undergo relevant questionnaires and blood sample collection after being informed of the content of the investigation, and to sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
年龄<18岁、少数名族、孕前糖尿病、妊娠期显性糖尿病、合并其他内分泌疾病(甲状腺疾病等)或心血管疾病(高血压等)、近2周有相关药物服用史 (糖皮质激素、激素避孕药、苯妥英钠、抗精神疾病药物等) 、非自然受孕、多胎妊娠、糖尿病急性或慢性并发症、肿瘤或其他严重肝肾功能不全、不同意参加研究等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Age <18 years; ethnic minorities; pre-gestational diabetes; overt diabetes during pregnancy; presence of other endocrine diseases (such as thyroid disease) or cardiovascular diseases (such as hypertension); history of relevant medication use within the past two weeks (e.g., corticosteroids, hormonal contraceptives, phenytoin, antipsychotic drugs, etc.); non-natural conception; multiple pregnancies; acute or chronic complications of diabetes; malignancies or other severe hepatic or renal insufficiency; unwillingness to participate in the study, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2025-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-20 00:00:00 至 To 2025-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
http://www.medresman.org.cn/,2026年1月之后 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org.cn/,after January 2026 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表,电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form,Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |